



PRESS RELEASE

SimuGen Completes a Major R&D Programme with Partner Company CPGR

16 September 2010. London (UK) and Kuala Lumpur (Malaysia)

SimuGen, a discovery pharmacogenomics company focused on predicting human toxicity early on in drug development, announced today that it has completed a major R&D programme with its partner; The Centre for Proteomic and Genomic Research (CPGR) in South Africa. This paves the way for a launch later this month, of SimuGen's flagship discovery pharmacogenomics software HT-Stream.

Dr Brian O'Keeffe, CEO of SimuGen, commented, "This is truly an important final step in preparing the company for the launch of our software product HT-Stream at the upcoming Cell-Based Assay Conference in London on 20th of September. SimuGen, together with its partner CPGR, has set up an impressive scientific collaboration, which can be built on in the coming time to ensure that HT-Stream continues to develop and realises its true potential as a leading edge software platform in the field of discovery pharmacogenomics".

Adds Dr Quin Wills, SimuGen CSO, "This has been a highly interdisciplinary programme, ranging from the optimisation of in vitro protocols and genomic assays to the mathematical modelling of human liver toxicity. It is rare to find such a broad focus in an R&D project, and we are very pleased with the outcome. We are confident that our customers will find the liver toxicogenomic models developed to be a step in the right direction for combining traditional, genomic and high content in vitro screening."

Said Dr Reinhard Hiller, Managing Director of the CPGR, "We are excited about having been part of this project as it has tested our ability to integrate leading cell biological assays with information-rich genomic workflows in a value-creating manner for SimuGen. In combination with SimuGen's HT-Stream bio-computational solution, we now can offer complete toxicogenomic workflows to enhance pre-clinical drug development in a unique way.

About SimuGen

SimuGen is a venture-backed pharmacogenomics company focused on predicting human toxicity early on in drug development. The company combines groundbreaking human cell and genomic modelling to produce high throughput screens for use alongside other early ADME testing. SimuGen's launching product, HT-Stream, is online high throughput screening software for analysing complex in vitro data.

More info on SimuGen and HT-Stream can be found on:

www.simugen-global.com and www.ht-stream.com

Asia Pacific

Unit T108, Suite 7.01, Level 7
The Gardens South Tower
Mid Valley City
59200 Kuala Lumpur, Malaysia
T +603 2264 5200
F +603 2264 5201

Europe

Suite 405
International House
1- 6 Yarmouth Place
London W1J 7BU
United Kingdom
T +44 (0)2033 264 283

info@simugen-global.com | www.simugen-global.com



SimuGen
intuitive genomics

About CPGR

The Centre for Proteomic & Genomic Research (CPGR) is an integrated core technology facility, founded in South Africa in 2006 as a not-for-profit organization through a grant provided by the Department of Science and Technology (DST) by way of its investment vehicles the Cape Biotech Trust (CBT) and PlantBio (PB). Visit www.cpgr.org.za for more information or contact info@cpgr.org.za with specific requests.

Asia Pacific

Unit T108, Suite 7.01, Level 7
The Gardens South Tower
Mid Valley City
59200 Kuala Lumpur, Malaysia
T +603 2264 5200
F +603 2264 5201

Europe

Suite 405
International House
1- 6 Yarmouth Place
London W1J 7BU
United Kingdom
T +44 (0)2033 264 283

info@simugen-global.com | www.simugen-global.com